디지털 hearing loss-related healthcare bio-venture Sound Vaccine announced that it has attracted strategic investment from Hana Bank based on its proprietary Threshold Sound Conditioning (TSC) technology.

At the core of Sound Vaccine’s business, TSC is a customized auditory stimulation technology that lowers the auditory threshold and induces recovery of hearing function in damaged frequency ranges. Its potential was validated through an exploratory clinical study at Stanford University School of Medicine in the United States, and it is regarded as a fundamental technology aimed at hearing management and improvement without drugs or surgery.

On the 8th, Sound Vaccine signed an investment agreement with Hana Bank for the acquisition of convertible bonds (CB). Based on the funds raised through this investment, the company plans to promote multinational confirmatory clinical trials of “ER134,” a TSC-based hearing improvement software designated as Innovative Medical Device No. 75 by the Ministry of Food and Drug Safety.

The two parties are also reviewing synergistic projects that combine financial infrastructure with healthcare technology. They are discussing the establishment of a B2B integrated settlement system connecting Sound Vaccine’s 32 distributors nationwide with hospitals and clinics, and are planning a non-face-to-face hearing check-up and hospital-linked B2C service by integrating the ER134 hearing assessment tool into Hana Bank’s mobile app “Hana One Q.”

This investment is reported to have been significantly driven by the research capabilities of CEO Eunyi Kwak, who holds a Ph.D. in Molecular Neurophysiology from Pohang University of Science and Technology, as well as the role of Director Sumin Lee, who oversaw IR and investment strategy. Lee, the eldest granddaughter of the late honorary chairman Jong-ho Lee of JW Pharmaceutical, led the fundraising process based on her understanding of the pharmaceutical and bio industries.

Popular News